“Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial”, J of Skin, vol. 9, no. 6, p. s652, Nov. 2025, doi: 10.25251/fmm5fj59.